CureDuchenne

CureDuchenne is recognized as a global leader in research, patient care, and innovation for improving and extending the lives of those with Duchenne muscular dystrophy. As the leading genetic killer of young boys, Duchenne affects more than 300,000 individuals living today. CureDuchenne is dedicated to finding and funding a cure for Duchenne by breaking the traditional charitable mould through an innovative venture philanthropy model that funds groundbreaking research, early diagnosis, and community education.

Debra Miller, the CEO and founder of CureDuchenne, serves as a patient representative on the TREAT-NMD Executive Committee.